Qing Ming Wang (Qing-Ming Wang, Qingming Wang)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

Multiple Myeloma

Chronic Kidney Disease

Prognostic Factors

Top Venues

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy (2023)
Zhan-Fa Zhang, Zhi-Yue Zhang, Yan Deng, Qing Ming Wang, Wei-Feng Zhu
Identification of a novel MICB allele, MICB*014:02, by cloning and sequencing. HLA (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Fu Ming Zi, Long Long Ye, Ji Fu Zheng, Jing Cheng, Qing Ming Wang
Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report. Medicine 100 (19) (2021)